SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Avalo Therapeutics reports $15 million in third-quarter R&D expenses

Avalo Therapeutics reported $15 million in research and development expenses for the third quarter.

AVTX

Related stories